Hepatic uptake and excretion of (-)-N-{2-[(R)-3-(6,7-dimethoxy-1,2,3,4- tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a novel if channel inhibitor, in rats and humans

Drug Metabolism and Disposition

Volumn 36, Issue 6, 2008, Pages 1030-1038

  Umehara, Ken Ichi ^a   Iwai, Megumi ^a   Adachi, Yasuhisa ^b   Iwatsubo, Takafumi ^a   Usui, Takashi ^a   Kamimura, Hidetaka ^a  

^a ASTELLAS PHARMA INC   (Japan)

^b SEKISUI CHEMICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT; CIMETIDINE; ESTRADIOL 17 GLUCURONIDE; IVABRADINE; MULTIDRUG RESISTANCE PROTEIN 1; N [2 [3 (6,7 DIMETHOXY 1,2,3,4 TETRAHYDROISOQUINOLINE 2 CARBONYL)PIPERIDINO]ETHYL] 4 FLUOROBENZAMIDE; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 1B1; ORGANIC ANION TRANSPORTER 1B3; ORGANIC CATION TRANSPORTER 1; QUINIDINE; YM 758;

ANIMAL CELL; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BILE LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG INHIBITION; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; HUMAN CELL; LIVER CELL; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BENZAMIDES; CATECHOLAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; CELL LINE; CELLS, CULTURED; HEPATOCYTES; HUMANS; ISOQUINOLINES; LLC-PK1 CELLS; OCTAMER TRANSCRIPTION FACTOR-1; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; P-GLYCOPROTEIN; RATS; SWINE;

ANGINA; MAMMALIA; RATTUS;

EID: 44149125534     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.020669     Document Type: Article

References (40)

1. Adachi Y, Suzuki H, and Sugiyama Y (2001) Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res 18:1660-1668.
2. Arndt P, Volk C, Gorboulev V, Budiman T, Popp C, Ulzheimer-Teuber I, Akhoundova A, Koppatz S, Bamberg E, Nagel G, et al. (2001) Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1. Am J Physiol Renal Physiol 281:F454-F468.
3. Bucchi A, Barbuti A, Baruscotti M, and DiFrancesco D (2007) Heart rate reduction via selective 'funny' channel blockers. Curr Opin Pharmacol 7:208-213.
4. Buckberg GD, Fixler DE, Archie JP, and Hoffman JI (1972) Experimental subendocardial ischemia in dogs with normal coronary arteries. Circ Res 30:67-81.
5. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, and Kim RB (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871.
6. Dudley AJ, Bleasby K, and Brown CD (2000) The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK(1) cell monolayers. Br J Pharmacol 131:71-79.
7. Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, Baumann C, Lang F, Busch AE, and Koepsell H (1997) Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 16:871-881.
8. Gorboulev V, Volk C, Arndt P, Akhoundova A, and Koepsell H (1999) Selectivity of the polyspecific cation transporter rOCT1 is changed by mutation of aspartate 475 to glutamate. Mol Pharmacol 56:1254-1261.
9. Gründemann D, Hahne C, Berkels R, and Schomig E (2003) Agmatine is efficiently transported by non-neuronal monoamine transporters extraneuronal monoamine transporter (EMT) and organic cation transporter 2 (OCT2). J Pharmacol Exp Ther 304:810-817.
10. Gründemann D, Liebich G, Kiefer N, Koster S, and Schomig E (1999) Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol 56:1-10.
11. Gunthorpe MJ, Smith GD, Davis JB, and Randall AD (2001) Characterisation of a human acid-sensing ion channel (hASIC1a) endogenously expressed in HEK293 cells. Pflugers Arch 442:668-674.
12. Hirano M, Maeda K, Shitara Y, and Sugiyama Y (2006) Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 34:1229-1236.
13. Indolfi C, Guth BD, Miura T, Miyazaki S, Schulz R, and Ross J Jr (1989) Mechanisms of improved ischemic regional dysfunction by bradycardia. Studies on UL-FS 49 in swine. Circulation 80:983-993.
14. Ishiguro N, Maeda K, Kishimoto W, Saito A, Harada A, Ebner T, Roth W, Igarashi T, and Sugiyama Y (2006) Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos 34:1109-1115.
15. Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, and Inui K (2005) Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 20:379-386.
16. Koepsell H, Schmitt BM, and Gorboulev V (2003) Organic cation transporters. Rev Physiol Biochem Pharmacol 150:36-90.
17. König J, Nies AT, Cui Y, Leier I, and Keppler D (1999) Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta 1461:377-394.
18. Laurent D, Bolene-Williams C, Williams FL, and Katz LN (1956) Effects of heart rate on coronary flow and cardiac oxygen consumption. Am J Physiol 185:355-364.
19. Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K, Hirano M, Watanabe T, Kitamura Y, Kusuhara H, et al. (2006) Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther 79:427-439.
20. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, and Sugiyama Y (2005) Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther 314:1059-1067.
21. Müller M and Jansen PL (1997) Molecular aspects of hepatobiliary transport. Am J Physiol 272:G1285-G1303.
22. Nozawa T, Tamai I, Sai Y, Nezu J, and Tsuji A (2003) Contribution of organic anion transporting polypeptide OATP-C to hepatic elimination of the opioid pentapeptide analogue [D-Ala2, D-Leu5]-enkephalin. J Pharm Pharmacol 55:1013-1020.
23. Opie L (1989) Trial alert. Cardiovasc Drugs Ther 3:795-796.
24. Roth W, Bauer E, Heinzel G, Cornelissen PJ, van Tol RG, Jonkman JH, and Zuiderwijk PB (1993) Zatebradine: pharmacokinetics of a novel heart-rate-lowering agent after intravenous infusion and oral administration to healthy subjects. J Pharm Sci 82:99-106.
25. Sakata T, Anzai N, Shin HJ, Noshiro R, Hirata T, Yokoyama H, Kanai Y, and Endou H (2004) Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. Biochem Biophys Res Commun 313:789-793.
26. Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP, Sheardown SA, Yue L, Burchard EG, Brett CM, et al. (2008) Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 83:273-280.
27. Sonnenblick EH, Ross J Jr, and Braunwald E (1968) Oxygen consumption of the heart. Newer concepts of its multifactoral determination. Am J Cardiol 22:328-336.
28. Storch CH, Theile D, Lindenmaier H, Haefeli WE, and Weiss J (2007) Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 73:1573-1581.
29. Sugiyama D, Kusuhara H, Shitara Y, Abe T, and Sugiyama Y (2002) Effect of 17 beta-estradiol-D-17 beta-glucuronide on the rat organic anion transporting polypeptide 2-mediated transport differs depending on substrates. Drug Metab Dispos 30:220-223.
30. Suzuki M, Suzuki H, Sugimoto Y, and Sugiyama Y (2003) ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem 278:22644-22649.
31. Tanigawara Y (2000) Role of P-glycoprotein in drug disposition. Ther Drug Monit 22:137-140.
32. Tian X, Li J, Zamek-Gliszczynski MJ, Bridges AS, Zhang P, Patel NJ, Raub TJ, Pollack GM, and Brouwer KL (2007) Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice. Antimicrob Agents Chemother 51:3230-3234.
33. 2-blockers on the organic cation transportersmediated transport between human (OCT) and rat (oct): insight into the application to the development of drug candidates. Xenobiotica 37:618-634.
34. Umehara KI, Iwatsubo T, Noguchi K, and Kamimura H (2007b) Functional involvement of organic cation transporter 1 (OCT1/Oct1) in the hepatic uptake of organic cations in humans and rats. Xenobiotica 37:818-831.
35. Urakami Y, Akazawa M, Saito H, Okuda M, and Inui K (2002) cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol 13: 1703-1710.
36. Urakami Y, Okuda M, Masuda S, Saito H, and Inui KI (1998) Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther 287:800-805.
37. Wu X, Huang W, Ganapathy ME, Wang H, Kekuda R, Conway SJ, Leibach FH, and Ganapathy V (2000) Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol 279:F449-F458.
38. Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, and Sugiyama Y (2006) Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos 34:1247-1254.
39. Yamazaki M, Suzuki H, and Sugiyama Y (1996) Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm Res 13:497-513.
40. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, and Giacomini KM (1997) Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol 51:913-921.